Aim: This systematic review and frequentist network meta-analysis used random-effects models is conducted to determine whether there are differences in the efficacy, acceptability, tolerability, and safety profiles of brexpiprazole (BRE) and aripi...
Taro Kishi Kenji Sakuma Masakazu Hatano Takenori Okumura Masaki Kato Hajime Baba Nakao Iwata
Neuropsychopharmacology reports 2024年2月
AIM: To update the major depressive disorder (MDD) treatment guidelines of the Japanese Society of Mood Disorders, we conducted a systematic review and pairwise meta-analysis of double-blind, randomized, placebo-controlled trials of available anti...
Yupeng He Masaaki Matsunaga Yuanying Li Taro Kishi Shinichi Tanihara Nakao Iwata Takahiro Tabuchi Atsuhiko Ota
JMIR Formative Research 7 e50193-e50193 2023年11月
Background
In Japan, challenges were reported in accurately estimating the prevalence of schizophrenia among the general population. Retrieving previous studies, we investigated that patients with schizophrenia were more likely to experience poo...
Journal of psychiatric research 167 132-138 2023年10月
The benefits of serotonin 3 receptor antagonists (5-HT3R-As) in obsessive-compulsive disorder (OCD) treatment remain unclear. Thus, this study aimed to perform a systematic review and a random-effects meta-analysis, including double-blind, randomi...
NEUROPSYCHIATRIC DISEASE AND TREATMENT 11 2299-2307 2015年
Objective: We conducted a systematic review and meta-analysis of the efficacy of aripiprazole once monthly (AOM) for schizophrenia.
Methods: Randomized controlled trials (RCTs) on AOM, published until June 25, 2015, were retrieved from PubMed, Coc...
お知らせ・マニュアル
医学部